ARPIM - The Romanian Association of International Medicine Manufacturers

Everything from polio to HIV to COVID-19 seemed, at times, unbeatable. But the search to turn science into treatments continues. With over 12,700 medicines and vaccines in development, just #Imagine how we can transform the way we prevent, manage, and cure diseases over the next decades. Discover EFPIA pipeline review: https://lnkd.in/ecaYvuNF #WeWontRest https://lnkd.in/eMFx-xse

One of the advantages of Romania's accession to the OECD will be attracting more investments to our country, and for this, good cooperation with the pharmaceutical industry is needed - Luca Niculescu - Secretary of State at the Ministry of Foreign Affairs and national coordinator for Romania's accession to the OECD. https://lnkd.in/dsjRVhab

The 2024 edition of Health at a Glance: Europe examines the major challenges facing European health systems in the aftermath of the COVID-19 pandemic. ✔️Urgent action is needed to address health workforce shortages in Europe ✔️Promoting healthy longevity can reduce the burden on health and long-term care systems ✔️Significant life expectancy gaps persist across countries and the health of young people is an enduring concern ✔️Progress in addressing lifestyle risk factors has stalled, with persistent socio-economic disparities ✔️EU countries have made gradual improvements in health crisis preparedness, but significant challenges remain in building public trust and combatting AMR

Innovation means progress, and in healthcare it is the only way to bridge the gap we have with current European treatment standards. Also, a competitive position to attract significant investments in pharmaceutical research and innovation can be a considerable economic advantage for Romania. We really appreciate the open and solutions-oriented dialogue we had today with Prof. Dr. Carmen Orban, State Counsellor. ✅ We met to discuss strategic #health objectives, to stimulate investments in the #medical sector, in research and innovation, and of course to discuss how we can improve patients' access to #innovative treatments.

"The development of the pharmaceutical industry remains a topic of permanent interest. The most pressing element within this development, directly related to the Ministry of Health, the National Health Insurance House, is the one that refers to people's access to medicines. However, this objective must be backed by a coherent policy in this field and that is what we are trying to do, to improve people's access to medicines through partnership with the industry. We want to have a partnership in the interest of people, and this partnership cannot be the subject of approaches that have no connection with reality and do nothing but discourage investments in the health sector. The pharmaceutical industry produces income for the Romanian state, produces jobs, but also offers patients access to medicines. At the moment, we have taken a step forward and, together with the Ministry of Economy, we have a structured working group that aims to provide the Government with a medium-term strategy at least, so that the development of the pharmaceutical industry is evident. The percentage of GDP that Romania has as medicine production is around 1% at the moment, we want it to reach 3%. The goal is to offer Romania a chance for economic development through the pharmaceutical industry, said Prof. Univ. Dr. Alexandru Rafila, Minister of Health, during the ARPIM event on 4th of November. https://lnkd.in/dTJtWTk7

A review of I Vote for Health campaign 2024 was captured in Revista Politici de Sănătate. ✔️All 400+ participants in the debates agreed that Health should be one of the main priorities of the Romanian Government in the next four years. ✔️Over 90% of participants supported a gradual annual increase in the budget allocation for Health, in order to reach the European average in the medium term. ✔️Increasing Health financing is an investment in the Romanian society and economy, which brings financial benefits to the state budget. Romania needs major investments in hospital infrastructure, from essential medicines and materials to public policies to keep doctors in the country. ✔️Access to the latest treatments must be accelerated to improve the health status of the population. Political actors must introduce Health as a priority chapter in government programs and collaborate with civil society to implement these public policies. ✔️There is an urgent need for a "Health Pact" and an implemented "Health Strategy". more details: https://lnkd.in/daeNuXXh Proud to be part of the I Vote for Health Coalition! #NewHealth #Sanatatea9

The pharmaceutical sector is a key #pillar of the #EU #economy: -       It is 3 times as productive as the European economy as a whole. -       It contributes €311 billion to the EU27 GVA - 2.0% of the total GVA -       It employs 2.3 million people At the same time, Europe’s life sciences ecosystem is facing intense competition. The Draghi report has set an ambitious goal: to close the innovation gap with the US and China. Let’s work together on policies to #RebootLifeSciences and make this a reality. Read more in our latest report: https://lnkd.in/dW2MY7is #WeWontRest

New research published today by EFPIA provides in-depth analysis of the economic footprint of the pharmaceutical industry in Europe, across Member States and compares Europe to other regions of the world. It shows a ‘strong and growing’ industry which contributed a total of €311bn to the EU-27 economy in 2022. The research shows that EU pharmaceutical R&D spending grew on average 4.4% per year between 2010 and 2022, from €27.8 billion to €46.2 billion. However, the data also provides further warning of the divergence in R&D spending between the EU and the other parts of the world, as Europe fails to keep pace with the growth seen in the sector in Asia and the US. https://lnkd.in/dTQr2_iB

The current theme of World Diabetes Day, marked each year on November 14, is “Diabetes and well-being.” This year’s global campaign emphasizes that the well-being of people with diabetes is not limited to the medical management of the disease. Factors related to mental and social well-being are essential to improving the quality of life of those with diabetes.

Ensuring the safety of medicines is a key obligation that regulators are constantly striving to fulfil, and a significant part of this assurance is the reporting of adverse events. However, it is regrettable that we are faced with the problem of underreporting, undermining our collective effort to ensure the safety of medicines for all users. This is a challenge that we must urgently address, given its implications for patient health. During the annual #MedSafetyWeek, Uppsala Monitoring Centre teams up with medicines regulators around the world to encourage reporting of side effects.